175 related articles for article (PubMed ID: 37749034)
1. [Efficacy and safety of programmed death-1 inhibitor in the treatment of relapsed/refractory classical Hodgkin's lymphoma].
Shan DD; Liu HM; Liu W; Huang WY; Lyu R; Deng SH; Yi SH; An G; Xu Y; Sui WW; Wang TY; Fu MW; Zhao YZ; Qiu LG; Zou DH
Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):555-560. PubMed ID: 37749034
[No Abstract] [Full Text] [Related]
2. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma.
Casadei B; Argnani L; Morigi A; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Cavo M; Zinzani PL
Cancer Med; 2020 Nov; 9(21):7830-7836. PubMed ID: 32881376
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy.
Rauf MS; Maghfoor I; Elhassan TA; Akhtar S
Med Oncol; 2015 Jan; 32(1):388. PubMed ID: 25429839
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab for the Treatment of Relapsed and Refractory Classical Hodgkin Lymphoma After Autologous Transplant and in Transplant-Naïve Patients.
Halahleh K; Al Sawajneh S; Saleh Y; Shahin O; Abufara A; Ma'koseh M; Abdel-Razeq R; Barakat F; Abdelkhaleq H; Al-Hassan N; Atiyyat R; Al-Faker N; Omari Z; Ghatasheh H; Jaradat I; Muradi I; Iyad S; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):589-595. PubMed ID: 35490153
[TBL] [Abstract][Full Text] [Related]
6. [Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis].
Qin Y; Zhao FY; Zhou Y; Jiang SY; Yang S; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1034-1039. PubMed ID: 33342160
[No Abstract] [Full Text] [Related]
7. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R
Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
9. A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin's lymphoma.
Gaudio F; Loseto G; Bozzoli V; Scalzulli PR; Mazzone AM; Tonialini L; Fesce V; Quintana G; De Santis G; Masciopinto P; Arcuti E; Clemente F; Scardino S; Tarantini G; Pastore D; Melillo L; Pavone V; Maggi A; Carella AM; Di Renzo N; Guarini A; Musto P
Ann Hematol; 2023 Feb; 102(2):385-392. PubMed ID: 36645458
[TBL] [Abstract][Full Text] [Related]
10. [Clinical Characteristics and Prognosis of 56 Lymphoma Patients with Mediastinal Masses].
Yu H; Wang L; Zhu HY; Wu W; Liang JH; Yin H; Fan L; Li JY; Xu W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):495-499. PubMed ID: 32319385
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
12. Real-World Experience of PD-1 Inhibitors for Relapsed and Refractory Hodgkin Lymphoma: A Multicenter Retrospective Analysis of Patients in China.
Yu W; Geng M; Hao J; Yan Z; Mi JQ
Acta Haematol; 2023; 146(4):307-315. PubMed ID: 37023729
[TBL] [Abstract][Full Text] [Related]
13. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
14. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
15. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
17. Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
Zhang YC; Wang JN; Ma SY; Cai J; Su N; Huang HQ; Li ZM; Xia ZJ; Huang H; Liu PP; Xia Y; Cai QQ
Br J Haematol; 2022 Jan; 196(1):127-135. PubMed ID: 34618912
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies.
Sun C; Chen H; Wang Y; Zheng C
Hematology; 2023 Dec; 28(1):2181749. PubMed ID: 36892260
[TBL] [Abstract][Full Text] [Related]
19. Impact of Risk Factors and Long Term Survival Analysis of Patients With Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant.
Akhtar S; Rauf MS; Elhassan TAM; Khan ZA; Elshenawy MA; Maghfoor I
Transplant Cell Ther; 2023 Jul; 29(7):451.e1-451.e12. PubMed ID: 37031748
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy.
Wang C; Liu Y; Dong L; Li X; Yang Q; Brock MV; Mei Q; Liu J; Chen M; Shi F; Liu M; Nie J; Han W
Clin Cancer Res; 2021 May; 27(10):2782-2791. PubMed ID: 33674274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]